Fig. 1.

First-line treatment of transplant-ineligible multiple myeloma (t translocation, del deletion, V bortezomib, R lenalidomide, d low dose dexamethasone). ^aIn patients treated initially with Rd, continuing treatment until progression is an option for patients responding well with low toxicity. ^bDexametahsone is usually discontinued after 1 year. ^cClinical trial strongly recommended as first option. [1]